最新发布
Immitra Bio raises CHF 2.4M for in-vivo gene editing
Why it matters: The ETH Zurich spinout is trying to replace the complex process used by current gene-edited cell therapies with an off-the-shelf injection that edits cells directly inside the body.
ICIS Introduces New rLDPE Pellet Pricing Reflecting Regulatory Driven Market Evolution
July 2026, London: Increased segmentation in Europe’s recycled low density polyethylene (rLDPE) market has prompte…
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
U.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. Rather than concentrating solely on artificial intelligence, the Stanford University spinout is betting on an overlooked biological driver of cancer: extrachromosomal circular DNA (eccDNA), small circular DNA molecules that exist outside chromosomes and may play a key role in tumor progression and treatment resistance.
Believer Meats trustee sets August 5 deadline for cultivated meat IP auction
The Israeli trustee tasked with selling the intellectual property assets of defunct cultivated meat startup Believer Mea…
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal
Samsung Biologics of South Korea has offered shareholders CHF44.31 per share in cash, valuing PolyPeptide’s equity at approximately CHF1.46 billion.
Blood Cancer Therapies Informed by Spatial Remodeling of Bone Marrow
In a new study published in Leukemia titled, “ Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasm , “ researchers from Weill Cornell Medicine have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms (MDS). The approach compares the size and shape characteristics of hematopoietic cells in the patient’s bone marrow sample with those in healthy bone marrow to generate a score that reflects disease severity.
氟吡菌酰胺首登杀线虫微囊制剂,复配阿维狙击黄瓜及番茄根结线虫
世界农化网中文网报道:近期,两项氟吡菌酰胺与阿维菌素复配的微囊悬浮-悬浮剂产品批准登记,分别是江西正邦的7%阿维菌素·氟吡菌酰胺ZC、河北赛丰的15%阿维菌素·氟吡菌酰胺ZC,分别登记用于黄瓜、番茄根结线虫防治。
Phytoform partners with major seed breeders to bring AI-powered plant design to corn crops
UK-based gene editing startup Phytoform is working with two of the world’s major seed companies—Beck’s Hybri…
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
辛菌胺作用机制新发现:不仅能″直接杀菌″,还能够让病菌″失去致病能力″
植物细菌性病害严重威胁水稻、果蔬等作物稳产提质。传统化学杀菌剂多依靠直接杀灭病原菌发挥药效,长期高频施用易形成强选择压力,诱导抗性菌株产生,病害防控可持续性不足。辛菌胺是中国拥有自主知识产权的烷基多胺类杀菌剂,具备低残留、环境友好、对非靶标生物安全等优势,已在农业生产中推广应用三十余年,田间至今未分离获得稳定抗性菌株。此前陈雨教授团队已有研究证实,辛菌胺可通过抑制细菌三羧酸循环与氧化磷酸化阻断能量合成、扰乱胞内铁稳态诱发氧化损伤并破坏病原菌DNA,发挥直接抗菌作用。但仅依靠直接抗菌机制,难以解释其低抗性风险背后的作用机制。
